The introduction of new non-steroidal anti-inflammatory drugs

Brooks, Peter; Buchanan, W. Watson

doi:10.1016/b978-0-407-02354-3.50021-x

Cited by 2 publications

(2 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These correlations depict the increase of celecoxib and etoricoxib anti-inflammatory action, with the increase of their penetration index. We know that there is a poor correlation between plasma concentration of an NSAID and its efficacy, 31 whereas the SF concentrations seem to have better correlation with clinical efficacy. 32,33 Moreover clinical efficacy of an NSAID seems to extend beyond that expected from halflife and this is probably due to the protracted decrease of inflammatory mediators in the joint.…”

Section: Discussionmentioning

confidence: 99%

In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis

Theodoridou

Gika

Diza

et al. 2017

MJR

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis

Theodoridou

Gika

Diza

et al. 2017

MJR

View full text Add to dashboard Cite

“…Indomethacin’s success would then in turn fuel the search for similar NSAIDs. Over the next several decades, some of these (such as benoxaprofen, see below) would be rejected due to safety concerns, while others would become mainstays of prescribing and self-medication, notably ibuprofen, naproxen, piroxicam and celecoxib (Abraham 1995 ; Brooks and Buchanan 1985 ).…”

Section: Phenylbutazone and Human Medicinementioning

confidence: 99%

Phenylbutazone (Bute, PBZ, EPZ): one drug across two species

Worboys

Toon

2018

HPLS

View full text Add to dashboard Cite

In this article we explore the different trajectories of this one drug, phenylbutazone, across two species, humans and horses in the period 1950–2000. The essay begins by following the introduction of the drug into human medicine in the early 1950s. It promised to be a less costly alternative to cortisone, one of the “wonder drugs” of the era, in the treatment of rheumatic conditions. Both drugs appeared to offer symptomatic relief rather than a cure, and did so with the risk of side effects, which with phenylbutazone were potentially so severe that it was eventually banned from human use, for all but a few diseases, in the early 1980s. Phenylbutazone had been used with other animals for many years without the same issues, but in the 1980s its uses in veterinary medicine, especially in horses, came under increased scrutiny, but for quite different reasons. The focus was primarily the equity, economics, and ethics of competition in equine sports, with differences in cross-species biology and medicine playing a secondary role. The story of phenylbutazone, a single drug, shows how the different biologies and social roles of its human/animal subjects resulted in very different and changing uses. While the drug had a seemingly common impact on pain and inflammation, there were inter-species differences in the drug’s metabolism, the conditions treated, dosages, and, crucially, in intended clinical outcomes and perceptions of its benefits and risks.

show abstract

The introduction of new non-steroidal anti-inflammatory drugs

Cited by 2 publications

References 81 publications

In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis

In vivo study of pro-inflammatory cytokine changes in serum and synovial fluid during treatment with celecoxib and etoricoxib and correlation with VAS pain change and synovial membrane penetration index in patients with inflammatory arthritis

Phenylbutazone (Bute, PBZ, EPZ): one drug across two species

Contact Info

Product

Resources

About